Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
19-nor-4-androstenedione is a synthetic anabolic-androgenic steroid (AAS) and a derivative of androstenedione. It is classified as a "prohormone" because it serves as a metabolic precursor to nandrolone (19-nortestosterone), an active anabolic steroid. After ingestion, it is converted in the body into nandrolone and other related hormones with androgenic activity. It was once marketed as a dietary supplement for bodybuilding purposes but has since been banned due to safety concerns and its classification as an anabolic steroid. The drug has no approved medical indications and is not used therapeutically[1][2]. Its mechanism of action involves conversion by endogenous enzymes into active steroids that bind to androgen receptors, promoting muscle growth and secondary male characteristics[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 19-nor-4-androstenedione.